Rinsho Shinkeigaku (Clinical Neurology)

Invited Review

Transition of Japanese clinical guidelines for myasthenia gravis

Hiroyuki Murai, M.D., Ph.D.1)

1) Department of Neurology, International University of Health and Welfare

The Japanese clinical guidelines for myasthenia gravis (MG) were revised in 2022. The major revision points in these guidelines are as follows. 1) A description of Lambert-Eaton myasthenic syndrome (LEMS) was included for the first time. 2) Revised diagnostic criteria of both MG and LEMS are proposed. 3) A high-dose oral steroid regimen with escalation and de-escalation schedule is not recommended. 4) Refractory MG is defined. 5) The use of moleculartargeted drugs is included. 6) MG is divided into six clinical subtypes. 7) Treatment algorithms for both MG and LEMS are presented.
Full Text of this Article in Japanese PDF (863K)

(CLINICA NEUROL, 63: 345|349, 2023)
key words: myasthenia gravis, guidelines, steroids, early fast-acting treatment, molecular targeted drugs

(Received: 27-Feb-22)